Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study recommends treatment change for pre-leukemia disease

14.03.2006


A new study finds that longer courses of a mild form of chemotherapy may help patients with a bone marrow disease only recently considered a form of cancer. Writing in the April 15, 2006 issue of CANCER, a peer-reviewed journal of the American Cancer Society, researchers say the study found that 45 percent of patients with Myelodysplastic Syndrome (MDS) who relapse did respond to a second course of treatment, but that the quality and duration of the second response was inferior to the initial treatment, leading researchers to believe that longer initial treatments may be more beneficial to patient outcome.



MDS is a bone marrow disease that causes an increasing number of dysfunctional blood cells called blasts to develop from stem cells and proliferate in the blood stream at the expense of normal cells. As a result, fewer normal red blood cells will circulate to carry oxygen to cells resulting in anemia; fewer white blood cells will be available to fight infections; and fewer platelets to control bleeding. Although MDS has not been considered cancer in the past, most hematologists (specialists in diseases of the blood) now think it is a form of bone marrow cancer (i.e. leukemia).

MDS generally afflicts adults over 50 years old, and therapy is supportive rather than curative. However, a subset of MDS patients will develop blood cell cancer, or leukemia. These high-risk patients have been shown to benefit from a new DNA hypomethylating agent, decitabine, undergoing clinical trials. The results of these trials are revealed in a related article by Kantarjian et al. also published in the April 15, 2006 issue of CANCER.


Little is known about the optimal duration of treatment with decitabine and the effect of retreatment for relapse. Led by Michael Lübbert, M.D., Ph.D. of the University of Freiburg Medical Center in Freiburg, Germany, researchers assessed the efficacy of decitabine retreatment on relapsing high-risk MDS patients who received initial treatment with decitabine.

The researchers found that retreatment with a median of three courses of decitabine resulted in 10 patients out of 22 (45 percent) achieving any response. Three of the patients achieved a partial or complete response in all three cell lines, while the other seven patients experienced hematologic improvements of an at least 50 percent drop in transfusion requirements and higher counts in one or two blood cell lines. The median overall survival of all patients from the start of the first decitabine course was 28 months. Decitabine-retreated patients had a median survival of 13 months from relapse

Decitabine retreatment in the 12 patients (55 percent) not achieving a second response either suppressed the abnormal cells without bone marrow repopulation with normal cells, resulting in cytopenia (blood cell deficiency), or had no effect on normal or abnormal cell lines. Of these 12 retreatment failures, four patients developed acute leukemia and three patients died of complications due to pathological deficiencies in cell lines.

The authors conclude, "results of the present analysis point to the importance of extending therapy with low-dose decitabine beyond the point of first response, and strongly support institution of a maintenance treatment." This type of continued outpatient maintenance treatment is presently studied by the authors in a multicenter clinical trial in older patients with acute myeloid leukemia.

David Greenberg | EurekAlert!
Further information:
http://www.wiley.com
http://www.interscience.wiley.com/cancer-newsroom

More articles from Studies and Analyses:

nachricht Multi-year study finds 'hotspots' of ammonia over world's major agricultural areas
17.03.2017 | University of Maryland

nachricht Diabetes Drug May Improve Bone Fat-induced Defects of Fracture Healing
17.03.2017 | Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Challenging European Research Project to Develop New Tiny Microscopes

The Institute of Semiconductor Technology and the Institute of Physical and Theoretical Chemistry, both members of the Laboratory for Emerging Nanometrology (LENA), at Technische Universität Braunschweig are partners in a new European research project entitled ChipScope, which aims to develop a completely new and extremely small optical microscope capable of observing the interior of living cells in real time. A consortium of 7 partners from 5 countries will tackle this issue with very ambitious objectives during a four-year research program.

To demonstrate the usefulness of this new scientific tool, at the end of the project the developed chip-sized microscope will be used to observe in real-time...

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

OLED production facility from a single source

29.03.2017 | Trade Fair News

Transport of molecular motors into cilia

28.03.2017 | Life Sciences

A novel hybrid UAV that may change the way people operate drones

28.03.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>